Business Context and Reporting Period
This Form 6-K filing by OKYO Pharma Ltd covers the reporting period ending December 15, 2025. The filing serves to disclose a specific corporate event regarding insider share acquisition rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure of share ownership changes and does not contain financial statements or operational metrics.
Material Changes
The primary material change disclosed is an increase in share ownership by an entity affiliated with the Executive Chairman:
- Acquirer: Panetta Partners Limited (an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest).
- Transaction: Acquisition of 24,551 ordinary shares on NASDAQ.
- Resulting Holding: Total beneficial interest increased to 10,516,297 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The document explicitly states that the attached news announcement (Exhibit 99.1) is furnished and not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of outstanding shares to calculate the Executive Chairman's updated percentage ownership.
- Review the attached Exhibit 99.1 for the full text of the news announcement regarding the share purchase.
- Confirm if this transaction triggers any additional reporting thresholds under applicable securities regulations.